AAIC 2022 | CSF tau as a biomarker of therapeutic effect

Johannes Streffer, MD, AC Immune SA, Lausanne, Switzerland, shares his thoughts on the value of cerebrospinal fluid (CSF) tau levels as a marker of therapeutic effect in Alzheimer’s disease (AD) clinical trials. Investigational agents working through several different mechanisms have demonstrated CSF tau lowering from baseline. Prof. Streffer suggests that this reduction in tau may be suggestive of a reduction in neurodegenerative processes and could therefore represent supporting evidence of a clinical effect. More work is needed to characterize CSF tau, how it changes over time, and what exactly its level reflects. This interview took place at the Alzheimer’s Association International Conference (AAIC) 2022 in San Diego, CA.